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a b s t r a c t
Cerebral malaria (CM) is a life-threatening complication of Plasmodium falciparum infection and repre-
sents a major cause of morbidity and mortality worldwide. The nature of the pathogenetic processes
leading to the cerebral complications remains poorly understood. It has recently emerged that in addi-
tion to their conventional role in the regulation of haemostasis, coagulation factors have an inﬂammatory
role that is pivotal in the pathogenesis of a number of acute and chronic conditions, including CM. Thiseywords:
lasmodium falciparum
erebral malaria
oagulation
aemostasis
new insight offers important therapeutic potential. This review explores the clinical, histological and
molecular evidence for the dysregulation of the coagulation system in CM, looking at possible underlying
mechanisms. We discuss areas for future research to improve understanding of CM pathogenesis and for
the development of new therapeutic approaches.
© 2009 Elsevier B.V. Open access under CC BY license.
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. Introduction
Cerebralmalaria (CM) is a severe form of Plasmodium falciparum
nfection that accounts for a large portion of the approximately
million acute malaria related deaths that occur annually. It is
iagnosed clinically when a P. falciparum infected person is deeply
nconscious with no other cause to explain the coma. It occurs
n individuals who have not acquired P. falciparum speciﬁc immu-
ity, with the burden being suffered overwhelmingly by children
n sub-Saharan Africa. A conspicuous pathological feature is the
dherence of P. falciparum infected erythrocytes (PfIE) in cerebral
essels [1]. However despite many years of research into its aeti-
logy and treatment, mortality remains high and the pathogenesis
s incompletely understood. In particular, the cause of death in this
yndrome remains unclear.
Infectionwith P. falciparum is associatedwith systemic endothe-
ial activation, patchy endothelial damage [2,3], lowplatelet counts,
ecreased levels of anticoagulants, generation of activated throm-
in andpro-coagulantmicroparticles [4–8]. This strongly suggests a
tate of dysregulation of the coagulation system. Clinically haemor-
hages are seen in themicrovessels in the eye inmost childrenwith
M and these correlate with multiple microthrombi and haemor-
hages in the microvessels of the brain in children who have died
9].
However gross clinical signs of coagulopathy are rare and tra-
itional functional indices of coagulation – namely prothrombin
ime and activated partial thromboplastin time – are generally only
ildly deranged. This leaves contention as to whether changes in
oagulation factors play a role in pathogenesis or aremerely a com-
lication of other underlying pathogenic processes thatmanifest in
few individuals with severe disease.
Other reviews have described the interaction between coag-
lation and malaria [10–12], this article focuses on the clinical
anifestations and biochemical features of dysregulation of coag-
lation in CM and explores the molecular mechanisms that might
ccount for these ﬁndings. We propose a theoretical model for the
ole of coagulation in CM, discuss potential therapeutic options and
rovide suggestions for future research in this area.
. Coagulation factors as inﬂammatory mediators and their
ole in sepsis
Normal haemostasis is a complex balance between pro- and
nti-thrombotic pathways that take place on endothelial or platelet
ell surfaces. This process involves the recruitment and tethering of
everal other cellular components includingneutrophils andmono-
ytes. Over the past 20 years, coagulation factors have emerged
s important mediators of inﬂammation that demonstrate cross-
alk with inﬂammatory cytokines [13]. These effects are involved
n the pathogenesis of a number of acute and chronic inﬂam-
atory conditions. The signalling events initiated by thrombin, a
entral coagulation molecule, are the best characterised. Throm-
in is capable of activating protease activating receptor 1 (PAR1), a
-protein-coupled receptor that, through modiﬁcation of nuclear
ranscription factors, can stimulate a multitude of inﬂammatory
vents, including recruitment and activation of platelets and leuko-
ytes and liberation of several pro-inﬂammatory cytokines [14].
It has become apparent that such inﬂammatory events may be
nitiated by coagulation molecules without overt clinical signs of a
oagulopathy, such as bleeding or thrombi. A state in which coagu-
ation is activated but balanced by regulatory pathways, termed
ompensated disseminated intravascular coagulation (DIC) [15],
as been shown in several large prospective clinical studies to be
redictive of poor outcome in bacterial sepsis in advance of clinical
igns [16]. Further evidence of the importance of such a com-al Parasitology 166 (2009) 99–108
pensated state comes from therapeutic trials with anticoagulants.
Treatmentwith infusions of the anticoagulantsAntithrombin III (AT
III) and activated protein C can attenuate mortality in animal mod-
els of bacterial sepsis [17,18] and activated protein C can improve
outcome in placebo-controlled trials in humans, even in individu-
als with no overt clinical signs of coagulopathy [19]. Furthermore,
activated protein C and AT III have anti-inﬂammatory effects and
a protective effect on the endothelium in vitro [20]. While thera-
peutic trials of these factors in humans have not had the dramatic
effect that was anticipated from animal trials, exciting new work
on modiﬁed factors that inﬂuence inﬂammation without increas-
ing risk of bleeding are in progress and may lead to the emergence
of highly effective therapies for sepsis in the future.
There are both similarities and differences between the patho-
genesis of P. falciparum infection and bacterial sepsis. The case for
a potent malaria toxin, like lipopolysaccharide or lipoteichoic acid,
remains controversial. Although the P. falciparum derived proteins
glycosylphosphotidylinositol and hemozoin have been shown to
have Toll-like receptor activity in vitro [21], it remains unclear how
important these effects are in vivo [22]. P. falciparum malaria is
an intravascular disease; whereas bacteria are able to traverse the
endothelium into extravascular tissue, P. falciparum rarely exits the
vessel lumen. Endothelial pathology occurs at sites of PfIE seques-
tration in the capillaries and post-capillary venules of end organs.
Widespread endothelial dysfunction resulting in shock, like that
seen in fulminant bacterial sepsis, is rare. However P. falciparum
infection does result in the activation of the endothelium and in the
release of pro-inﬂammatory cytokines [3,23]; mechanism impli-
cated in the activationof coagulation inbacterial sepsis and so some
similarities in the effects of both kinds of infection on the regulation
of coagulation at the endothelial surface seem likely (Table 1).
3. Clinical manifestations of coagulopathy
3.1. Gross haemorrhage and thrombosis
While gross haemorrhagic or thrombotic events are uncommon
in CM, their occurrence highlights a clear interaction between P. fal-
ciparum infection and coagulation.Overt bleeding is rare in children
but in adults occur in approximately 5% of cases of CM, most com-
monly from the gastrointestinal tract [24]. Bleeding events have
been described from other sites in association with CM, includ-
ing rare severe bleeding episodes such as extensive bleeding into
the skin associated with areas of necrosis called purpura fulminans
[25,26], pulmonary haemorrhage [27] and intracranial bleeding
[28–31]. Gross thrombotic events have also been described at post
mortem in a few case reports; intracranially in the dural sinus [32]
and in the lungs as thromboembolism [33]. Limb gangrene requir-
ing limb amputation has also been described [34].
3.2. Microthrombi and ﬁbrin deposits
Petechiae like lesions in thebrain in fatal CMwereﬁrst described
nearly a century ago by Dudgeon and Clarke who recognised that
the combination of thrombosis and haemorrhage seen in these
patients might indicate that a coagulopathic state contributes to
disease [35]. Recently detailed immunocytochemical studies using
thrombin andplatelet-speciﬁc antibodies have shown these lesions
to be thrombi surrounded by ring haemorrhages as well as thrombi
in intact vessels without haemorrhage (Wassmer, unpublished
data). Among Malawian children with CM approximately 75% have
thrombi [1]. These lesions are also seen in adults who have died
from CM but are less common and tend to be ﬁbrin deposits
without platelets [2,36]. In fatal paediatric CM, brain thrombi
and microhaemorrhages are conﬁned to the capillaries in which
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Table 1
Description of some key coagulation molecules.
Molecule Function SF or TMR Site of expression Effect in P. falciparum malaria
TF Main activator of coagulation
cascade
TMR Expressed in all vessels on underlying cells of basal lamina
and the basement membrane. Expressed on activated
endothelial cells, monocytes, platelets and microparticles
Severe malaria: NI
CM: TF expression on endothelium in cerebral
vessels in CM and associated with thrombi [81]
Mechanism: PfIE cause upregulation of TF on
endothelium in vitro in contact dependant
manner [49,81]
Thrombin Converts ﬁbrinogen to ﬁbrin.
Inﬂammatory mediator via PAR1
signalling
SF Produced from prothrombin on activation of coagulation.
Very rapidly inactivated and therefore difﬁcult to measure
directly
Severe malaria: Raised TAT complexes [4,6,8]
and Fibrinopeptide A [113] indicate increased
thrombin generation. Correlate with severity of
infection [4,6]
CM: NI
Protein C Inhibits production of thrombin and
anti-inﬂammatory when activated
SF Circulates in inactive form until activated by
thrombomodulin and EPCR initiated by the binding of
thrombin to thrombomodulin
Severe malaria: Decreased antigen and activity
[4,6,7]
CM: NI
Thrombomodulin Inhibits thrombin by binding and
involved in activation of protein C
TMR Expressed on all vascular endothelium although at a lower
lever in the brain. Cleaved from the membrane to become a
soluble factor when there is endothelial damage
Severe malaria: Circulating thrombomodulin
increased [68]; effect on endothelial
thrombomodulin expression not reported
CM: NI
EPCR Involved in activating protein C by
stabilising the interaction of protein C
with the thrombin–thrombomodulin
complex
TMR Expressed on all vascular endothelium; lower level in microvessels NI
AT III Inhibits thrombin both directly
and upstream
SF Activated by heparin sulphate Severe malaria: Antigen and activity levels
decreased [6,7]
CM: NI
Fibrin Fibrin strands form a mesh that
associates with platelets to form a clot.
Also pro-inﬂammatory
N/A Produced from ﬁbrinogen in the presence of thrombin.
Once produced forms clumps and can only be measured by
surrogate markers of its breakdown
Severe malaria: Evidence for increased ﬁbrin
generation in some studies [101,114] but
ambiguous
CM: Deposits of ﬁbrin or thrombi in vessels in
diseased organs [1,2,9]
SF: soluble factor; TMR: trans-membrane receptor; NI: not investigated.
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fIE sequester [1]. These children frequently also have thrombi in
icrovessels of other organs that show sequestration; namely the
ut, lung, kidney, subcutaneous fat (Whitten RO, personal commu-
ication) and in the retina [9]. Thrombi are rarely seen in vessels
ithout sequestration, implying a focal pathology that is mediated
y interactions with PfIE.
Lesions seen at autopsy could be caused by peri-morbid events
nd might not be representative of pathology in vivo. However
etinal haemorrhages have been shown to correlate strongly with
aemorrhages in the brain at autopsy, but can also be seen in
he majority of surviving patients with CM, implying that these
esions are a component of pathology in the acute phase of the
isease [9,37,38]. Retinal haemorrhages have a central white area,
here microthrombi have been shown by histology [9]. The num-
er of haemorrhages seen at fundoscopy correlates with risk of
eath. These data show that in children with CM although gross
oagulopathy is not common, microvascular coagulopathy occurs
requently and is associated with poor prognosis.
. Mechanisms for the activation of coagulation
Malaria is an intravascular disease—the parasite does not invade
he brain tissue or that of other target organs. The pathology of
alaria in these tissues is therefore determinedby thedisruption of
he normal intravascular environment. This may lead to the activa-
ionof the coagulation systemin fourdifferentways: (1) endothelial
ctivationbypro-inﬂammatory cytokines; (2) circulatingmicropar-
icles and activated platelets; (3) endothelial damage; (4) contact or
inding between parasite-derived proteins on the PfIE surface and
oagulation-based receptors on the endothelium or on circulating
lood cells.
.1. Endothelial activation
Endothelial activation in P. falciparum infection results in the
pregulation of adhesionmolecules on the endothelial surface that
re implicated in PfIE adherence and pathogenesis: vonWillebrand
actor (vWF), VCAM-1, ICAM-1, P-selectin and E-selectin [3,39–41].
his may occur indirectly via an intermediate factor that is affected
y PfIE, for which inﬂammatory cytokines are the main candidate,
r directly by interaction between parasite-derived molecules and
ndothelial receptors. A recent study performed in human volun-
eers demonstrated that vWF and vWF propeptide release from the
eibel–Palade bodies were signiﬁcantly increased early in P. falci-
arum blood-stage infection, implying acute endothelial activation
41]. In African childrenwith P. falciparummalaria, vWF levelswere
ssociated with severity, with the highest levels being observed in
M and non-CM severemalaria [39]. vWF is a largemultimeric gly-
oprotein involved both in platelet adhesion and aggregation, and
s produced predominately by activated endothelial cells. When
eleased, vWF is inanactivatedconformation,whichallows interac-
ion with the platelet receptor gpIa/V/IV and triggers intravascular
latelet aggregation [42]. This function primarily occurs under high
hear stress conditions on the arteriolar side of the microcircula-
ion [43]. One possible mechanism for increased vWF levels might
e decreased activity of the vWF-cleaving protease ADAMTS13 (a
isintegrin and metalloproteinase with a thrombospondin type 1
otif, member 13) and ADAMTS13 activity has been shown to be
educed in other conditions associatedwith thrombocytopenia and
aised vWF levels, such as bacterial sepsis and thrombotic throm-
ocytopenic purpura [42]. However in early experimental malaria,
aised vWF and thrombocytopenia were not accompanied by a
hange in ADAMTS13 activity [41]. These results suggest that a
ifferent mechanism for increased vWF levels may be implicated
n malaria. The release of large multimers of vWF and adherental Parasitology 166 (2009) 99–108
platelets into the circulation might provide multiple binding sites
for PfIE and could potentially lead tomajor rheological disturbances
by generating circulating clumps of vWF, platelets and PfIE. The
possible association between an increase in vWF andmortality still
remains to be investigated in adult and paediatric CM.
In vitro, endothelial nitric oxide (NO) decreases tissue factor
(TF) expression [44] and is the major inhibitor of the exocytosis of
Weibel–Palade bodies. It has recently been shown that endothelial
NO is reduced in severe malaria in adults and is associated with
increased concentrations of angiopoietin-2, an angiogenic factor
also stored in Weibel–Palade bodies [45]. As vWF is copackaged
with angiopoietin-2 in Weibel–Palade bodies, these results might
explain the increase of vWF release in adult CM, leading to endothe-
lial activation. While there is no published data in paediatric CM, it
is entirely possible that a similar decrease in vascular NO avail-
ability occurs, leading to: (1) an increased expression of TF by
microvascular endothelial cells, leading to an activation of the coag-
ulation cascade and (2) a substantial augmentation in exocytosis of
Weibel–Palade bodies with a subsequent increase of vWF release.
Both effects could respectively explain not only the dysregulation
of coagulation observed in paediatric CM, but also the characteristic
acute endothelial activation inherent in this pathology.
The role of pro-inﬂammatory cytokines in the pathogenesis of P.
falciparummalaria has been extensively studied.While several can-
didate cytokines for the activation of the coagulation system exist,
TNF (formerly TNF-) is the candidate with the best characterised
role in CM [23,46]. PfIE can induce TNF production in several ways,
the most important being either directly through the endothelium
or via recruitment of monocytes [47]. In addition to its well known
pro-inﬂammatory effects, TNF can also activate coagulation. It is a
potent stimulator of TF, the major initiator of the coagulation cas-
cade [48],whichoccurs through the activationofNFB [49] and this
effect is upregulated synergistically in the presence of thrombin
via MAP kinase signalling [48]. TNF can also inhibit the activa-
tion of protein C by causing downregulation of thrombomodulin
transcription [50].
4.2. Microparticles
Microparticles are vesiculations of the plasma membrane of
eukaryotic cells, shed during physiological or pathogenic processes
such as activation or apoptosis; they have been a topic of increas-
ing interest in a number of disease states. Althoughmany aspects of
microparticle function are still unclear, a picture develops in which
microparticles play an important role in inﬂammation, coagula-
tion, and vascular homoeostasis. They have recently been shown
to activate coagulation in vitro and to participate in thrombus
formation in a model of vessel injury via their surface expres-
sion of TF and phosphatidylserine [51]. TNF is a potent agonist of
endothelial vesiculation, leading to a dramatic increase in the pro-
duction of endothelial microparticles. These microparticles display
a pathogenic phenotype by expressing both cell adhesion and cat-
alytic surface phospholipids able to trigger the extrinsic pathway
independently of TF [52–54]. A recent study in Malawian children
demonstrated signiﬁcantly higher levels of circulating endothelial
microparticles during the acute phase of CM compared to levels
observed in parasitaemic controls. Levels of endothelial micropar-
ticles correlate positively with plasma levels of TNF and return
to normal following recovery [5]. The enumeration of micropar-
ticles is carried out by ﬂow cytometry and can be difﬁcult due
to their small size and the resolution of basic ﬂow cytometers.
However, ﬂuorescence labelling allows microparticles to be differ-
entiated from the background noise. In addition, a clean machine,
ﬁltered buffers and a proper dilution of the sample before analy-
sis prevent a too high number of events passing through the laser
and insure a better accuracy of the readings. It is not yet known
hemic
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f increased numbers of microparticles simply reﬂect an infection
nduced endothelial alteration or if they have a speciﬁc pathogenic
ole in CM.
Recently, analyses in a mouse model of CM [46] provided evi-
ence for both pro-inﬂammatory and pro-coagulant effects of
icroparticles produced acutely in the plasma of CM suscepti-
lemice. Indeed,microparticle-stimulatedperitonealmacrophages
ere able to produce extremelyhigh levels of TNF, reaching thepro-
uction observedwhen stimulated by bacterial lipopolysaccharide,
ne of the most potent TNF inducers. In addition, microparticles
ere able to reduce signiﬁcantly the clotting time of uninfected
ouseplasma [55]. Althoughmousemodels havebeena signiﬁcant
esource in advancing knowledge of this disease, further investiga-
ions of the direct role of microparticles in human CM are needed.
.3. Platelet adhesion to endothelium
Thrombocytopenia is an almost invariable feature of acute P.
alciparum infection and appears to involve immune mechanisms,
latelet activation, removal by the reticulo-endothelial system and
onsumption in different steps of coagulation [56]. The accumu-
ation of platelets in cerebral microvessels in human CM was ﬁrst
escribed by electron microscopy [57], and more recently a post
ortem study performed in Malawian children revealed that the
ccumulation of platelets in the brain was speciﬁc to children with
diagnosis of CM, as opposed to children who were parasitaemic
ut who had another cause of death [58].
Several studies performed with an in vitro model of the cere-
ral pathology showed that platelets can either adhere directly to
he surface of TNF-stimulated endothelium via speciﬁc molecules
uch as platelet CD41 and endothelial CD40 [59], or adhere to vWF
ultimers at the surface of activated endothelium [39]. Having
dhered to theendothelial surface, platelets are able to formbridges
etween PfIE and cerebral endothelium by providing new parasite
eceptors tobrainendothelial cells initiallydevoidof them[59]. This
henomenon has been demonstrated in vitro and platelets lining
he brainmicrovasculature between endothelial cells and PfIE have
eendescribed inahistopathological studyof thebrainofMalawian
hildrenwho succumbed to CM [58]. Interestingly, PfIE can activate
latelets in vitro by contact [60] leading to the transfer of TF stored
n their alpha-granules to the platelet surface. Activated platelet
urface TF may also derive from not only binding of TF-positive
icroparticles but also splicing of TF pre-mRNA and translation of
he mature mRNA into protein. Indeed, human platelets express TF
re-mRNA and, in response to activation, splice this intronic-rich
essage into mature mRNA. Splicing of TF pre-mRNA is associ-
ted with increased TF protein expression [61]. Once at the cell
urface, TF may require activation to reveal its pro-coagulant activ-
ty. Provided that this phenomenon occurs in vivo, it might lead to a
ramatic platelet activation loop by initiating coagulation and pro-
oting endothelial apoptosis, with both phenomena leading to an
ncrease in platelet activation.
.4. Endothelial damage and apoptosis
The endothelium acts as an envelope of uncharged cells devoid
f TF, separating the blood from the negatively charged and
F-expressing connective tissue. Under normal physiological con-
itions this allows the blood to circulate without the activation of
oagulation factors. When endothelial damage occurs, these circu-
ating blood factors are exposed to both TF and a negative charged
urface with resultant activation of coagulation through the TF
athway. While this mechanism is protective in cases of haemor-
hagedue tovascular trauma, it also contributes to thepathogenesis
f conditions in which endothelial cells are altered through inﬂam-
ation, apoptosis or hypoxia. It is implicated in the coagulopathiesal Parasitology 166 (2009) 99–108 103
and organ dysfunction that occur in sepsis [62] and dengue haem-
orrhagic fever [63].
Inmousemodels of severemalaria several lines of evidence sug-
gest that there is damage to the endothelium causing an increase in
the permeability of vessels, particularly in the brain [46]. Surrogate
markers for endothelial apoptosis are raised [64,65] and endothe-
lial damage on retinal whole mounts of mice with experimentally
induced CM has been described [64].
Such severe endothelial damage is rare in humans with P.
falciparum infection but there is evidence to support a more
subtle involvement of microvascular endothelial damage in the
development of CM. Post mortem histological examination of cere-
bral microvessels by electron microscopy showed patchy areas
of damaged endothelial cells amidst intact endothelium [2]. In
vivo, assessment of retinal perfusion in patients with CM using
angiography occasionally revealed multiple tiny areas of leakage,
demonstrating focal areas of breakdown of the blood retinal barrier
[66]which is structurally analogous to the blood–brain barrier [67].
However, extracellular oedema to imply gross blood retinal barrier
breakdown is rare. Evidence that subtle endothelial damage occurs
in a wider group of patients is also implied because levels of the
endothelial bound receptor thrombomodulin is raised in peripheral
blood, presumably because it is shed from the endothelial surface
and levels are higher in patients with more severe disease [68].
One cause of endothelial damage that seems likely to be impor-
tant in CM is apoptosis, which is also a speciﬁc cause of activation of
coagulation [69]. Themechanism for apoptosis in vivo has not been
established but in vitro PfIE adhesion on TNF-stimulated endothe-
lial cells is strongly pro-apoptotic [70,71], an effect exacerbated by
a prior co-culture with platelets [71]. This effect is mediated by the
cytokine TGF- released from alpha-granules of activated platelets
[54]. Suchapathogenicmechanismmaybe important in vivo topro-
mote endothelial apoptosis at sites of platelet–PfIE sequestration
and in the presence of high levels of circulating TNF.
4.5. Receptor–ligand interactions between infected red blood cells
and the host endothelium
Infection with P. falciparum leads to the expression of multiple
parasite-derived proteins on the surface of the PfIE. Several families
of theseproteinshavebeendescribed; theyarehighly variable,with
coding regions generally located in sub-telomeric zones. Parasite-
derived proteins interact with host receptors on the surface of the
vascular endothelium and this interaction is a key factor in the
pathogenesis. However, it has become apparent that these interac-
tions may also have other important effects downstream. Binding
of parasite-derived proteins on PfIE to dendritic receptors has been
shown to prevent their maturation [72]. In addition, signalling
events induced by PfIE adhesion can modify the surface expres-
sion of endothelial receptors [73,74]. The importance of low afﬁnity
interactions between parasite-derived proteins and endothelial
receptors, including those that regulate coagulation, has received
surprisingly little attention and yet the potential of these interac-
tions seems large; both as PfIE roll along the endothelium prior to
binding and during binding when the PfIE and its surface proteins
are brought into direct apposition with the endothelium. Given
the expression of several coagulation receptors at the endothelial
surface, receptor–ligand interactions with PfIE may either inter-
ferewith the normal physiological interactions or induce signalling
events that alter the regulation of coagulation. Although a speciﬁc
ligand–receptor interactionhasnotbeendemonstrated, a signalling
mechanism is implicated in the activation of TF when it is upreg-
ulated on the endothelial surface during infection, as described
below. The thrombomodulin receptor involved in the activation of
protein C and heparin sulphate, involved in the activation of AT III
are other potential candidates since a portion of these molecules
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re binding sites for PfIE. The effects of these interactions on coag-
lation have not yet been explored.
. Effect of P. falciparum on coagulation pathways
.1. Activation of coagulation by tissue factor
TF is a transmembrane receptor expressed constitutively in
ost vessels in the cells under the endothelium. When it binds
o factor VII, TF acts as the principal activator of coagulation. TF
an be presented to factor VII as a result of endothelial damage,
ut also by circulating macrophages, platelets or microparticles
r when it is upregulated at the endothelial surface. Many stim-
li can induce such endothelial TF expression, including TNF [75],
nterferon gamma [76] and thrombin [77]. Upregulation of TF by
ipopolysaccharide in bacterial sepsis leads to a reinforcing inter-
lay between inﬂammation and coagulation [78]. In inﬂuenza and
ytomegalovirus infections there is an upregulation of surface TF on
onocytes, associatedwith both acute symptoms and an increased
isk of atherosclerosis [79].
In vitro, PfIE can induce expression of surface TF on puriﬁed
onocytes [80] and on cultured endothelial cells [49,81]. Although
NF is a candidate mediator, in vitro experiments suggest that PfIE
nduction of TF on endothelial cells is mediated by contact [81].
nterestingly, the upregulation of TF on endothelial cells is only
nduced by PfIE in their late life cycle, implying the involvement
f an antigen that is only expressed in mature stages.
In vitro, PfIE can induce the expression of TF on puriﬁed mono-
ytes [80] and on cultured endothelial cells [49,81]. While TNF is a
andidatemediator, in vitroexperiments suggest that PfIE induction
f TF on endothelial cells is mediated by contact [81]. Upregulation
f TF on endothelial cells is only induced by PfIE containing late-
tage parasites, implying the involvement of an antigen that is only
xpressed by mature PfIE stages.
In vivo, the upregulation of TF has been associated with placen-
almalaria and CMpathologies. In placentalmalaria, ﬁbrin deposits
mpingingon the intervillous spaces are associatedwith theexpres-
ion of TF on macrophages [82]. In CM, paediatric brain autopsy
ections show TF expression on the endothelium of pre- and post-
apillary vessels [81], a feature associated with thrombi and ring
aemorrhages.
A drug developed to block TF activity which is a conjugate of the
atural inhibitor of the TFpathway– tissue factor pathway inhibitor
reduced mortality in a primate model of sepsis [83], but did not
mprove outcome in a large intervention trial of sepsis in humans
84]. It has not been investigated whether this drug has any effect
n outcome in severe malaria.
.2. Protein C
The protein C pathway is a key modulator of both the inﬂam-
atory and haemostatic systems. Three main constituents of this
athway – protein C, protein S and thrombomodulin – have been
hown to be affected in P. falciparum infection. In vivo evidence for
he importance of the role of this pathway in the pathogenesis of
nfection has been demonstrated in Gram-negative sepsis, where
downregulation of protein C and thrombomodulin receptors on
he endothelium are associated with microvascular thrombus for-
ation in the dermis of children with meningococcal disease [85].
urthermore activated protein C reduced mortality in a large dou-
le blind placebo-controlled trial of adults with severe bacterial
epsis, making it the only adjunctive treatment in sepsis of proven
fﬁcacy [19]. Consideration of activated protein C is of particu-
ar interest in malaria since in addition to its anticoagulant and
nti-inﬂammatory effects it is also anti-apoptotic [20], protectsal Parasitology 166 (2009) 99–108
endothelial barrier function [86] and reduces neuronal apoptosis
secondary to ischemia [87]. Hence its actions might be protective
against some of the underlying mechanisms associated with cere-
bral malaria pathogenesis.
Protein C and its cofactor, protein S, are vitamin K dependent
plasma glycoproteins. Protein C is activated through the receptors
thrombomodulin and endothelial protein C receptor (EPCR) when
thrombin binds thrombomodulin. Activated protein C and S then
form a complex that inhibits further thrombin production. Acti-
vated protein C also acts independently as an anti-inﬂammatory
agent [88]. Hence the activation of protein C acts like a molecular
switch inwhich thepro-coagulant, pro-inﬂammatory factor throm-
bin triggers the availability of an anticoagulant, anti-inﬂammatory
factor.
In vivo plasma protein C antigen and activity [4,6,8] are
decreased in P. falciparummalaria infection. Levels show an inverse
correlation with clinical severity [6] and parasite density [4] and
improve with treatment, correcting to within normal range in con-
valescence. Similarly protein S levels tend to be lower acutely in
patients with severe but not mild P. falciparum infection and are
lowest in patients with severe complications [6,7]. These studies
were predominately in adults and including few patients with CM.
Wewouldexpect theeffectson these factors tobemorepronounced
in CM but studies are needed to investigate this particularly in
African children.
The effectiveness of activated protein C as a treatment has not
been systematically investigated. Case reports of patients with
severe P. falciparum malaria infection improving following treat-
mentwithactivatedproteinC [89,90] are insufﬁcient toprove safety
or efﬁcacy in malaria at present.
5.3. Thrombomodulin
Activation of protein C is initiated by binding of thrombo-
modulin and decreased activation of protein C in bacterial sepsis
has been shown to relate to downregulation of thrombomodulin.
These factors point to thrombomodulin as a primary candidate
to explain the decreased activation of protein C in P. falciparum
infection. Thrombomodulin is an integral membrane glycoprotein
expressed on nearly all endothelial tissue although notably only
at low levels in the brain [91]. A side chain of thrombomodulin,
chondroitin sulphate A (CSA), increases the anti-thrombotic prop-
erties of thrombomodulin 10–20-fold [92] and this side chain can
bind PfIE [93]. While the importance of PfIE binding to thrombo-
modulin in sequestration is unclear, low afﬁnity interaction with
the thrombin binding site and therefore the activation of protein C
could lead to a decreased capacity to buffer thrombin, although this
mechanism is yet to be explored. Decreased availability of throm-
bomodulin may also occur due to raised TNF, which can induce a
downregulation of thrombomodulin on cultured endothelium [94],
or by shedding of thrombomodulin from the endothelium, which
can be induced in vitro using serum from P. falciparum infected
patients [68].
5.4. Antithrombin III
AT III is another major endogenous anticoagulant and anti-
inﬂammatory agent [95]. It is a circulating glycoprotein that can
inhibit thrombin directly and via a number of upstream factors.
AT III has poor anticoagulant activity until activated, principally by
heparin sulphate.Like protein C, AT III plays an important role in the aetiology of
sepsiswith levelsbeingnegativelyassociatedwith severityandout-
come [96]. Infusion of AT III prevents mortality in an animal model
of sepsis [17] and has shown some success in placebo-controlled
trials in humans with DIC and sepsis [96].
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Levels of AT III antigen [7,8] and activity [6] are decreased in
evere P. falciparum infection. Levels correlate with severity and
here is rapid recovery following antiparasitic treatment [6]. Low
ntigen levels are likely to be due to increased consumption from
hrombin binding in thrombin–antithrombin (TAT) complexes as
AT complexes are signiﬁcantly increase in severe malaria [4,8];
uggesting AT III is ‘mopping up’ excess thrombin. Decreased activ-
ty may reﬂect a decreased availability of antigen or may reﬂect
ompromised activation by heparin sulphate. Since heparin sul-
hate is a major binding site for parasite-derived proteins [97], a
ossible mechanism for the latter is that PfIE ligands interact with
eparin and compromise the heparin dependent activation of AT
II.
Since heparin can also disrupt rosette formation [98] and
nhibits parasite invasion and growth [99,100], heparin like drugs
re potential therapies and in a simian model of malaria, treat-
ent with heparin resulted in a decrease in mortality [101]. The
nly controlled studies to look at heparin treatment in humans
102,103] were not powered to detect an improvement in outcome
nd World Health Organization guidelines do not recommend the
se of heparin in malaria because of the potential to induce haem-
rrhage [104]. Heparinoids such as curdlan sulphate that disrupt
fIE binding but that have a lower risk of causing bleeding may
epresent an alternative. In two small studies, although not pow-
red to show effect on mortality, curdlan sulphate decreased time
ntil clearance of feverwith no noted side effects and the beneﬁcial
ffect was most noted in individuals with CM [105].
. Theoretical model and possible reasons that
aemorrhage occurs more in the brain
Using available evidence we propose a model for the involve-
ent of dysregulation of coagulation in the pathophysiology of
M in which intense sequestration in microvessels leads to a
einforcing cycle of inﬂammatory and coagulant events result-
ng in focal endothelial damage, thrombi and microhaemorrhage
Fig. 1). Inﬂammatory events are also likely to increase sequestra-
ion through upregulation of receptors on the endothelial surface
uch as ICAM-1.
ig. 1. Theoretical model for the dysregulation of the coagulation system in cerebral mala
ost immune response and parasite-derived protein interactions with host endothelium,
ignalling through PAR; (2) the activation and recruitment of platelets and monocytes;
xcessive visibility of TF on the following activated components: endothelium, platelet
rotein C and AT III pathways (latter not pictured here). However, at the most severe end o
he microvasculature (b). This sets up a potential positive feedback cycle of inﬂammatory
hich adheres to activated platelets to form thrombi and is itself pro-inﬂammatory. Exce
ytokines, unbuffered by anticoagulants, and activation of apoptosis by PfIE contact and T
aps in vessels and, in the context of excessive local consumption of coagulants by the thral Parasitology 166 (2009) 99–108 105
The observation that thrombi and haemorrhage occur to a
greater extent in the brain than in other organs in which parasites
sequester requires further consideration. It cannot be explained
purely by the degree of sequestration, as sequestration is not
signiﬁcantly higher in the brain than in other organs in which
thrombi and haemorrhage are less common [106]. The implication
is therefore that cerebral microvessels are somehow predisposed
to decompensation. One possible explanation is the low levels of
thrombomodulin expression in vessels in the normal human brain
[91] and the low levels of EPCR found inmicrovessels. The potential
for cerebral microvessels to activate protein C would therefore be
low, even in the absence of pathology. These vessels would then be
prone to decompensation resulting in thrombi and haemorrhage
earlier than in other organs. Another hypothesis is that the dis-
tinct expression pattern of endothelial receptors in the brain,which
leads to a different proﬁle of PfIE-receptor binding – such as an
increased tendency tobind ICAM-1 in theabsenceofCD36receptors
– also leads to qualitatively different PfIE–endothelial interac-
tions. This may be associated with different resulting signalling
events more likely to result in conditions that favour haemorrhage.
A better understanding of the speciﬁc interactions between PfIE
and the coagulation and inﬂammatory system, particularly at the
endothelial level will help guide our understanding ofwhy cerebral
endothelium might be affected differently to endothelium in other
organs.
7. Adaptive responses to minimise coagulopathy
Given the degree of interaction between PfIE and the endothe-
lium and the extremely high levels of parasitaemia observed in
many children with CM, some with >40% of erythrocytes being
infected, it is surprising that coagulation is not more dysregulated.
However this can be considered in the light of a long evolution-
ary history of human infection by this parasite. The evolutionary
pressureofP. falciparumon thehumanhost is probably themost sig-
niﬁcant of any parasitic interaction [107] and this has resulted in a
number of geneticmutations to confer protection, such as sickle cell
anaemia and thalassemia. Similar pressure was applied by the host
on the parasite and has led to the development of elaboratemecha-
ria. (a) Early in infection the coagulation system is activated by a combination of the
and circulating cells. This leads to: (1) the generation of thrombin and intracellular
(3) the vesiculation of microparticles from the endothelium and platelets; (4) an
s, monocytes and microparticles. In most patients this system is balanced by the
f the spectrum these pathways are impaired by intense sequestration of PfIE within
and coagulation events. Thrombin promotes the conversion of ﬁbrinogen to ﬁbrin
ssive inﬂammation at these sites from a combination of inﬂammatory events and
GF-, leads to endothelial damage and loss of tight junction function. This creates
ombi, leads to microhaemorrhages. L-: lymphotoxin-; IL-6: interleukin-6.
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isms for evading the host immune system. Induction of thrombi or
aemorrhage is deleterious to the host because it alters blood sup-
ly to vital organs and deleterious to the parasite as parasites in PfIE
onsumed in thrombi or that leak out of the vessel by haemorrhage
re unable to then infect new erythrocytes. A hypercoagulable state
ould havedramatic effects for both organisms; it is thereforemost
ikely that both organisms would have developed mechanisms to
inimise the activation of the coagulation system.
Several host factors produced in response to infection are pro-
ective against inﬂammatory damage. Among them, erythropoietin
108] may be raised up to 30-fold in CM and reaches levels associ-
ted with protection against inﬂammation and tissue damage in
troke. Parasites can also exert a protective effect on the endothe-
ium. Indeed, it has been reported that in some cases PfIE but not
ninfected erythrocytes induce in vitro a downregulation of TNF-
ssociated apoptosis in a contact dependentmanner [109]. It seems
ighly plausible that there are many other host and parasite mech-
nisms that protect against activation of the coagulation system
oth downstream by limiting inﬂammation and directly. Further
nvestigation of these mechanisms is required not only to improve
ur understanding of parasite–host interactions but also to provide
ew therapeutic approaches for CM.
. Suggestions for future research
The majority of published work on the coagulation system in
alaria comes from studies on soluble factors and on traditional
oagulation assays. In trying to understand the role of coagulation
n CM, these studies have several limitations: (1) they are predom-
nately carried out in adult populations and are from areas of low
r inconstant transmission of P. falciparum and therefore are not
epresentative of the paediatric groupwho suffer themajor burden
f disease in sub-Saharan Africa; (2) the number of patients with
evere disease in these populations is small and there are no stud-
es speciﬁcally on CM; (3) they aremainly in study populations that
re epidemiologically poorly characterised and (4) severe malaria
s investigated as a heterogeneous group without distinguishing
alarial syndromes, which may have different aetiologies. In addi-
ion, recent studies have led to the development of newassays [110]
nd to a consensus scoring systemthat allowsmore consistent char-
cterisation of a pro-coagulant state [15] and it has been shown that
hese tools enable prediction of outcome in advance of clinical signs
16]. Investigation of plasma factors in a well characterised group
f African children with CM that incorporate these developments
s warranted.
However factors in blood can only give a downstream pic-
ure of the regulation of coagulation, which occurs principally
t the endothelial surface. Studies of endothelial events have
emonstrated changes in the endothelial expression of coagula-
ion receptors in sepsis and in neoplastic disease that have shed
ight on their underlying pathology [85,111]. But there has been lit-
le published on the changes to endothelial coagulation receptors
n malaria. Looking at such local events is particularly relevant in
disease like P. falciparum malaria in which disease occurs princi-
ally in microvessels; since focal events here might be important
ocally in end organs but not be detectable in peripheral blood.
o accurately understand the contribution of coagulation to CM
athology we must therefore be able to explore endothelial events
n the small vessels of affected tissues. Onemeans of doing this is to
ook at microvessels in post mortem tissue. This has the advantage
f allowing the explorationof endothelial events in several different
rgans in one individual andwehave discussed interestingwork on
F expression that has used thismethod [81]. However information
rom patients post mortem only provides information on advanced
isease and includes events that may only occur in the agonal oral Parasitology 166 (2009) 99–108
post mortem period. A group has looked at studying endothelial
receptor expression in skin biopsies ex vivo but found that events
in skinmicrovesselswere poorly representative of the extent of dis-
ease [112], perhaps because there is minimal sequestration in this
tissue. Development of a representative ex vivo model would be
invaluable.
Endothelial events can also be explored in vitrobyusing cultured
endothelial monolayers and parasites to explore host–parasite
interactions.Models exist for studying such interactions under ﬂow
conditions to mimic the sheer forces encountered in the intravas-
cular environment. Studies using such techniques have given us
valuable insights intodiseasemechanismsboth in termsofadhesive
and signalling events, and could be used to look at coagulation-
based events in CM.
9. Conclusion
Although obvious thrombosis or haemorrhage have been con-
sidered rare inP. falciparum infections, detailedpostmortemstudies
and examination of the retina in vivo have revealed that microvas-
cular lesions are common in children with CM. A number of
coagulation related molecular and cellular events underlie these
changes and are apparent even in patients with less severe dis-
ease. Given the importance of coagulation factors as regulators
of inﬂammation these events are likely to play an important role
in pathogenesis. However there is a paucity of research directed
speciﬁcally at CM or at endothelial phenotype in malaria and there
remain signiﬁcant gaps in our understanding of the exact nature
and mechanisms responsible for these changes. Advances in this
area may play an important role both in our understanding of CM
pathogenesis and also in the development of new therapies and
prognostic tools.
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